About IBB ETF
Overview: iShares Nasdaq Biotechnology ETF offers exposure to the biotech sub-sector of the health care industry, serving up access to a group of stocks that can thrive on technological breakthroughs and increased investment in medical processes. IBB is primarily focused on U.S. stocks, though a smattering of international firms adds some degree of international diversification. This biotech ETF casts a considerably wider net than the other ETF options for exposure to the space, investing in more than 100 stocks. That feature can be particularly important in the biotech space, where company-specific developments can send a single stock soaring. IBB is somewhat top-heavy, but generally spreads exposure across large caps, mid caps, and small cap stocks. This ETF is ideal for investors seeking long term growth by investing in disruptive biotech companies. About the Fund Manager: Founded in 1988, Blackrock is the largest asset manager in the world managing $6.28T. BlackRock operates globally with 70 offices in 30 countries and clients in 100 countries. Due to its power and the sheer size and scope of its financial assets and activities, BlackRock has been called the world's largest shadow bank.. Recommended for: Growth
Returns
| Performance | YTD | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|
| Blackrock Biotechnology ETF | -1.30% | 32.64% | 14.19% | 10.32% | 16.15% |
Asset Class
Asset type breakdown
IBB Holdings - Top 10
| Namei | Weightage (%) | |
|---|---|---|
| Amgen Inc | 9.23% | |
| Gilead Sciences, Inc | 6.93% | |
| Illumina, Inc | 5% | |
| Vertex Pharmaceuticals Incorporated | 4.64% | |
| Moderna, Inc | 4.54% | |
| Regeneron Pharmaceuticals, Inc | 4.25% | |
| Biogen Inc | 3.43% | |
| Alexion Pharmaceuticals, Inc | 2.88% | |
| Seagen Inc | 2.22% | |
| AstraZeneca PLC | 1.93% |
IBB Sectors/Industry Breakdown
| Sectori | % of market value | |
|---|---|---|
| Healthcare | 100% |
IBB Countries
| Countryi | % of market value | |
|---|---|---|
| North America | 91.05% | |
| Europe Developed | 3.56% | |
| Asia Emerging | 3.04% | |
| United Kingdom | 2.05% | |
| Africa/Middle East | 0.15% | |
| Asia Developed | 0.15% |
Projected Returns
Returnsbased on historic SIP returns of 13.31% per annum
IBB Summary Data
| Total Net Assets | $ | i |
| Average Mkt Cap Mil | $ | i |
| Symbol | IBB | |
| Exchange | XNAS | |
| ISIN | US4642875565 |
| Cat. Benchmark | MSCI ACWI NR USD | |
| Asset class | Equity | |
| Category | Health | |
| Country | US |
IBB Portfolio Data & Volatility Analysis
| Net Expense Ratio | 0.46 | i |
| Beta | 0.91 | i |
| Valuations Rates Portfolio PE | 12.61142 | i |
| 3 Year Standard Deviation | 22.99 | i |
Fund Strategy
iShares Nasdaq Biotechnology ETF is an exchange-traded fund incorporated in the USA. The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index. The Fund will concentrate its investments in companies primarily engaged in using biomedical research for the discovery or development of new treatments or cures for human disease.
IBB Fact Sheets & Reports
About iShares by Blackrock
"iShares" is a gathering of ETFs managed by Blackrock. Blackrock is an American investment management corporation founded in 1988. Some iShares ETFs are actively managed but most funds track a bond or share market index.
